Early Imatinib Mesylate-Induced Hepatotoxicity in Chronic Myelogenous Leukaemia-Reference-Cited by-同舟云学术

Early Imatinib Mesylate-Induced Hepatotoxicity in Chronic Myelogenous Leukaemia

Published:2007 Issue:4 Volume:118 Page:205-208
ISSN:0001-5792
Container-title:Acta Haematologica
language:en
Short-container-title:Acta Haematol

Author:

Kong Jee Hyun,Yoo Seung-Hyun,Lee Kyoung Eun,Nam Seung Hyun,Kwon Jung Mi,Lee Sang Min,Chang Hye Jung,Choi Moon Young,Cho Min Sun,Mun Yeung-Chul,Nam Eunmi,Lee Soon Nam,Seong Chu-Myong

Publisher

S. Karger AG

Subject

Hematology,General Medicine

Reference17 articles.

1. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

3. Imatinib mesylate as a cause of acute liver failure

4. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of the role of NLRP3 inflammasome activation in new-generation BCR-ABL1 tyrosine kinase inhibitors-induced hepatotoxicity;Toxicology Letters;2024-10

2. Tumours and Tumour-Like Lesions;MacSween's Pathology of the Liver;2024

3. Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins;MacSween's Pathology of the Liver;2024

4. The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review;International Journal of Clinical Pharmacy;2023-12-26

5. Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis;Science Signaling;2023-01-17